Assessment of common red blood cell pretreatments to yield an accurate serologic antigen phenotype compared with genotype-predicted phenotype

T. Horn/ J. Hamilton/ J. Kosanke/ V.W. Hare/ W. Kluver/ W. Beres/ S. Nance/ M.A. Keller

For patients requiring multiple transfusions and patients with positive direct antiglobulin tests (DATs), an extended red blood cell (RBC) phenotype can provide valuable information and help to determine the risk of forming alloantibodies. In some instances, the phenotype may be used for prophylactic matching. Phenotyping in this patient population is often hindered by the presence of circulating donor cells and/or by a positive DAT. Several methods, such as EDTA glycine acid (EGA) treatment to (..)

DOI: 10.21307/immunohematology-2019-020

Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn

K.J. Moise/ Y. Morales/ M.F. Bertholf/ S.N. Rossmann/ Y. Bai

Only rare cases of anti-Vel–associated mild-to-moderate hemolytic disease of the fetus and newborn have been previously reported. No case of fetal anemia requiring prenatal therapy has been noted to date. We report such a case recently encountered at our Fetal Center. Strategies are discussed for managing pregnancy complicated with alloimmunization to an antibody to a high-prevalence antigen, including sources of red blood cells for intrauterine transfusions.

DOI: 10.21307/immunohematology-2019-021

Separation of multiple antibodies by adsorption with allogeneic red blood cells

E.M. Ekema

Antibody detection and identification are processes that are commonly performed in the transfusion service before transfusion of allogeneic red blood cells (RBCs). Antibody identification usually follows the discovery of a positive antibody detection test, or other factors such as ABO serum/cell discrepancy or an incompatible crossmatch. Antibody identification is a necessary practice in blood banking to determine the suitability of blood products for transfusion on an individual basis. When the(..)

DOI: 10.21307/immunohematology-2019-022

Hemovigilance and the Notify Library

B.I. Whitaker/ D.M. Strong/ M.J. Gandhi/ E. Petrisli

Hemovigilance systems allow reporting of adverse occurrences associated with blood transfusion to a central database where events can be reviewed and analyzed for the benefit of patients and donors. Hemolytic and serologic transfusion reactions are among the many types of reactions reported to these systems. The Notify Library, a database of adverse events associated with medical products of human origin, has incorporated hemovigilance into its didactic resources. Students and practitioners are (..)

DOI: 10.21307/immunohematology-2019-023

Clinical and laboratory profile of anti-M

D. Basu/ S. Basu/ M. Reddy/ K. Gupta/ M. Chandy

Anti-M is a frequently detected naturally occurring antibody that has been reported in various clinical settings and also in voluntary donors. We describe here the clinical and laboratory findings of 11 cases with anti-M detected at our center. This report is a retrospective study in which we reviewed our immunohematology laboratory records for cases involving anti-M. Both donor and patient data from a 28-month period (September 2014 to December 2016) were reviewed. During this period, 11 exampl(..)

DOI: 10.21307/immunohematology-2019-024

Dithiothreitol treatment of red blood cells

C.B. Bub

Dithiothreitol (DTT), a reducing reagent, has multiple applications in blood bank testing. DTT disrupts the bridging of the disulfide bonds between amino acid residues necessary for structural conformation of some proteins and the bonds holding an IgM molecule in the pentameric formation. DTT treatment of red blood cells (RBCs) can denature or modify certain blood group antigens—in particular, those in the Kell, Lutheran, YT, JMH, LW, Cromer, Indian, Dombrock, and Knops systems—and prevent recog(..)

DOI: 10.21307/immunohematology-2019-025

Thank You

Sandra Nance/ Cynthia Flickinger

DOI: 10.21307/immunohematology-2019-026

ERRATUM

DOI: 10.21307/immunohematology-2019-027